Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-103

I read the Quarterly, it’s unsurprising if you read all of the ANNs. R&D costs are large, trial start ups have the largest costs with CRO & trial sites in the beginning. Multiple now ongoing with a good cash reserve.

We also have new hires in the USA to facilitate the Professional & Scientific running of the company with an increased US presence.

That ‘Small Capex’ interview with LC was pathetic. Aren’t they owned by ‘Next Incestors’?

Not on LC’s part but an interviewer that couldn’t get his head around anything & maybe shouldn’t be interviewing on complex Immunology/Oncology Biotech stocks with more than 1IP in the pipeline to get your head around, try all of IMU’s it’s hard to keep up! That whole interview was derailed I think & LC managed it graciously. End game, it won’t matter.